Celularity emerges from SPAC merger doubled down on cell therapies as Bob Hariri downgrades ill-fated Covid-19 program
It took a few months longer than expected, but Bob Hariri has finally guided Celularity and its placental-derived cells to Wall Street.
Merging with GX Acquisition Corp gives Celularity $138 million to work with as Hariri pushes the NK cell and T cell therapies deeper into early-stage trials.
The biotech, which has drawn attention for a high-profile effort to test an NK cell infusion early in the pandemic, has all but thrown in the towel on Covid-19, prioritizing instead cancer indications such as acute myeloid leukemia and glioblastoma multiforme — conforming closer to its peers in cell therapy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters